Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Global Crohn's Disease (CD) Treatment Market Snapshot (2023 To 2033)

The global Crohn's disease treatment market is slated to reach a valuation of US$ 11.68 billion by the end of 2023. According to Future Market Insights, the market is projected to rise at a steady 4.3% CAGR until 2033, being valued at US$ 17.80 billion.

Over the coming years, market growth is predicted to be fueled by the increasing incidence of ulcerative colitis along with Crohn's disease worldwide. Over than 1.6 million Americans experience ulcerative colitis or Crohn's disease, and almost 70,000 new instances of IBD are thought to be identified in the USA each year, as reported by the Crohn's & Colitis Foundation of America. Furthermore, over than 80,000 people in Australia have IBD, based on the RAH Research Fund report.

Growth in the market is anticipated to be fueled by the availability of a robust product pipeline and anticipated releases over the forecast period. For instance, phase II clinical studies are now underway for AbbVie's ABBV-154, an anti-TNF GRM ADC that is anticipated to be on sale in the next years. Comparable to this, Lilly's Mirikizumab is a sizable molecule that may be studied as a therapy for Crohn's disease and is anticipated to be on sale in 2023. Modern treatments concentrate on lowering complication risks, inflammation, and sustained remission. In addition, hospitals and healthcare organizations collaborate closely with pharmaceutical firms to carry out clinical trials and guarantee patient safety. Such initiatives are anticipated to improve research efforts to provide a cutting-edge Crohn's disease therapy.

Also, a crucial development in the market for treating Crohn's disease is the growth of technology. For instance, the market's top players in the treatment of Crohn's disease are placing a strong emphasis on the use of cutting-edge technologies like artificial intelligence (AI) for drug development and the provision of novel therapies for ulcerative colitis and Crohn's disease. Leading firms and tech entrepreneurs are working together to achieve technical advances so they may take use of each other's technology and abilities to develop unique procedures and increase their market positions. For instance, in May 2021, the Israeli tech startup CytoReason announced a deal with Ferring Pharmaceuticals to use AI technology to speed up the drug development process and discover new therapies for Crohn's disease. Developments as such are expected to boost the global revenues in the market for the treatment of Crohn's disease globally from 2023 to 2033.

Data Points Key Statistics
Anticipated Base Year Value (2022) US$ 11.2 billion
Expected Market Value (2023) US$ 11.68 billion
Projected Forecast Value (2033) US$ 17.80 billion
Global Growth Rate (2023 to 2033) 4.3% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 To 2022 Crohn's Disease Treatment Market Demand Analysis Vs. Forecast 2023 To 2033

The global Crohn's disease treatment market grew at a CAGR of 3.2% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.

Any area of the small or large intestine may be affected by Crohn's disease. It may involve many segments, or it could be continuous. Some individuals only have the illness in their colon, which is a section of their big intestine. Thus, these symptoms leads on to more of inflammatory bowel diseases and ultimately leads to Crohn’s disease.

Moreover, market expansion is anticipated to be supported by the rise in the use of initiatives including product launches, innovation, expansions, and partnerships. For instance, RINVOQ, a Janus kinase inhibitor, was approved by the USA FDA in March 2022 for the treatment of Crohn's disease. Moreover, AbbVie, Inc. declared the completion of its purchase of Allergan in May 2020, which is anticipated to increase the company's product line for the treatment of Crohn's disease. Moreover, throughout the course of the projected period, market expansion is predicted to be supported by the growing use of innovative products and big molecules. As a result, the global Crohn's Disease Treatment Market is expected to forecast a CAGR of over 4% from 2023 to 2033.

Prominent Growth Drivers Influencing Crohn's Disease Treatment Market

Increasing adoption of biologics have been accelerating the demand

Biological therapy such as anti-interleukin & integrin antibodies and anti-tumor necrosis factor (TNF) are frequently utilised for many inflammatory disorders such as Crohn's disease (CD). For treating individuals who cannot be well managed by steroids or aminosalicylates, they are typically regarded as sufficient.

Nevertheless, some individuals may stop responding to these treatments, especially anti-TNFs. There is a desire for treatments with novel MOAs which are less immunogenic than currently available options, and several new classes of medicines are hoping to hit the market within the next few years. Stelara (ustekinumab) is the last biologic licensed for Crohn's disease.

Due to their improved clinical profiles and practical patient dosage, biologics including anti-integrin as well as interleukin inhibitors are gaining ground in the Crohn's Disease market. Hence, the market for Crohn's disease treatment is anticipated to grow throughout the course of the projected period as a result of these developments.

Rising incidence of Inflammatory Bowel Diseases is driving growth

The market under study has shown significant expansion, which may be attributed to the rising incidence of Crohn's disease and inflammatory bowel illnesses globally. According to projections, there will be 18,30,734 people with Crohn's disease in the 8MM in 2021. Between 2023 and 2033, this number is anticipated to increase to 21,91,544.

As per an article published in 2021 by Journal BMC Gastroenterology, there will be an expected rise of 2.5 fold rise in IBD cases in Iran, and 2.3 fold rise in North America by 2035. Such factors are expected to boost the demand for various therapies and treatments for the diagnosis of Crohn’s disease.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What Could Possibly Hinder Crohn's Disease Treatment Market Demand?

Lack of reimbursement policies and high cost are expected to hinder the growth

There is lack of awareness among the various patients suffering from Crohn’s disease in various countries across the globe. Additionally, the higher cost for this kind of treatment, including the drug as well as other cost is expected to restrain the growth of the Crohn’s disease treatment market.

Furthermore, in developing countries like India, Russia and China, there is a scarcity of reimbursement policies for Crohn’s disease treatment, restraining the adoption of the drugs in these regions. The aforementioned issues thus restrict the growth of the Crohn's Disease Treatment Market.

Region-wise Analysis

What Is the Outlook of the North American Crohn's Disease Treatment Market?

Presence of key players and increasing initiatives are accelerating the growth

During the forecast period, the North American market for Crohn's disease treatment is expected to be the most volatile one. As per Future Market Insights, this region is expected to proliferate at a CAGR of 4.9% from 2023 to 2033.

Due to the existence of several powerful market participants and the numerous strategic efforts they have made in the area, they have achieved this dominance. Regional development is additionally made possible by the rising prescription of innovative treatments, improved payment practises, and high treatment rates in the area. The continued development of innovative treatments and supporting governmental policies are also expected to fuel the region's growth. One of the major organizations that supports numerous clinical and translational studies to identify treatments for colitis and Crohn's disease, for instance, is the Crohn's & Colitis Foundation.

Hence, during the forecast period, the North American region can be expected to show a significant growth rate, acquiring a global market share of 42% in the year 2023.

What Can Be Expected from The Asia Pacific Market for Crohn's Disease Treatment?

Enhanced healthcare facilities and strong patient pool to accelerate the growth

During the forecast period, the Asia Pacific market for Crohn's disease treatment is expected to garner a CAGR of 3.6%. Some of the key reasons driving market expansion in the next years include an ageing population, a high chance of acquiring inflammatory illnesses, an increase in the incidence of inflammatory bowel disorders, Crohn's disease, and better healthcare policies in the area.

Also, increased investments by top players in the area and the increasing acceptance of biosimilar and biologics are anticipated to fuel market expansion in the near future. Hence, factors such as these are expected to accelerate the growth in the regional market from 2023 to 2033.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Which drug type segment is expected to gain traction from 2023 to 2033?

The immunomodulators segment will gain the dominant market share

Over the course of the forecast period, the immunomodulators segment by drug type is anticipated to occupy a significant share of the global Crohn's Disease Treatment Market. In 2023, this category is anticipated to dominate with a 53% revenue share.

Due to their superior therapeutic activity, the immunomodulators subgroup of medication types now occupies a leading position in the worldwide Crohn's disease therapy market. The key advantage of these medications is that they lessen the long-term requirement for steroids and stop recurrent flares. Because of this, immunomodulators are occasionally referred to as "steroid-sparing" medications. They may also be used with other medications, such as biologics, to assist avoid the development of antibodies, which can reduce the effectiveness of biologics. Such factors are expected to accelerate the growth prospects for Crohn's disease treatment from 2023 to 2033.

Which distribution channel segment is expected to gain traction during 2023 to 2033?

The hospital pharmacies segment will demand during the forecast period

According to a report by Future Market Insights, the hospital pharmacy industry would grow within the anticipated time frame. This market sector is expected to hold a 27.3% share of the worldwide market from 2023 to 2033.

Due to the growing number of people visiting hospitals for advice on treatment related to Crohn's disease, the hospital pharmacies sector is anticipated to dominate the worldwide Crohn's disease treatment market. For instance, up to 80% of those suffering from Crohn's required hospitalization at a certain point in 2020, according to an article posted by WebMD LLC, a web publisher of data pertaining to human health and well-being. As a result, these individuals are expected to only buy medications from hospital pharmacies.

Start-up Scenario

The start-ups in this sector aim to use a number of techniques, such as the launch of new products and acquisitions, to improve their market positions internationally.

  • In order to treat patients with Crohn's disease and ulcerative colitis, Gusto Global, a microbiome discovery platform firm dedicated to restoring a healthy microbiome, has created unique bacterial consortia. Gusto's bottom-up rational collaborative design methodology, which is assiduously guided by mechanistic modeling and insights from microbiome ecology and disease etiology, is validated by best-in-class preclinical findings for a Living Biotherapeutic Product.
  • Using its implanted neuromodulation device, SetPoint Medical is commencing a clinical study to treat Crohn's disease patients. The vagus nerve is stimulated, which is believed to activate the body's inherent anti-inflammatory reflexes and reduce the symptoms of inflammatory illnesses.

How Competitive is the Market for Crohn's Disease Treatment?

New therapies based on the microbiome and utilizing unique pathways are being developed to treat Crohn's disease. Prominent businesses in the sector are creating unique goods, investing heavily in research and development, and engaging in big acquisitions and partnerships.

Some of the prominent players in the global market for Crohn's disease treatment are:

  • Abbvie Inc.
  • Celgene Corporation
  • Genetech
  • Johnson & Johnson
  • Pfizer Inc.
  • Prometheus Laboratories Inc. (Nestle)
  • Salix Pharmaceuticals Inc.
  • Takeda's Pharmaceutical Ltd
  • Janssen Pharmaceuticals
  • Biogen
  • AstraZeneca

Some of the important developments of the key players of the market are:

  • With Enterome S.A., Takeda has reached a global license, co-development, and co-promotion agreement. A lot of companies, including Enterome, 4D Pharma, BiomX, Synlogics, Vedanta Bioscience, and others, are concentrating on microbiome-based therapies to cure illness. For their product portfolio to be strengthened, these players use both organic and inorganic expansion techniques.
  • For the treatment of moderate-to-severe Crohn's disease, a number of biologics have already approved, including the Remicade (infliximab), Cimzia (certolizumab pegol), the anti-integrins Entyvio (vedolizumab), anti-TNFs Humira (adalimumab), and Tysabri (Natalizumab), and the interleukin (IL) 12 and (Risankizumab-rzaa). The market for treating Crohn's disease now has five main firms with branded medications approved: Takeda, Johnson & Johnson (J&J), AbbVie, UCB, and Biogen.

Report Scope

Report Attribute Details
Growth Rate CAGR of 4.3% from 2023 to 2033
Market value in 2023 US$ 11.68 billion
Market value in 2033 US$ 17.80 billion
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units US$ Billion for Value and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Drug type
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • United States
  • Canada
  • Brazil
  • Mexico
  • United Kingdom
  • Spain
  • Germany
  • Italy
  • France
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Malaysia
  • Thailand
  • Australia
  • New Zealand
  • South Africa
  • GCC Countries
Key Companies Profiled
  • Abbvie Inc.
  • Celgene Corporation
  • Genetech
  • Johnson & Johnson
  • Pfizer Inc.
  • Prometheus Laboratories Inc. (Nestle)
  • Salix Pharmaceuticals Inc.
  • Takeda Pharmaceutical Ltd
  • Janssen Pharmaceuticals
  • Biogen
  • AstraZeneca
Customization & Pricing Available on Request

Key Segments Covered in the Crohn's Disease Treatment Market Report

By Drug Type:

  • Antibiotics
  • Amino Salicylates
  • Corticosteroids
  • Immunomodulators
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the Current Crohn’s Disease (CD) Treatment Market Size?

As of 2023, the Crohn's Disease treatment market holds a valuation of US$ 11.68 billion.

What are the Growth Prospects for Crohn’s Disease (CD) Treatment Market in the Next Decade?

The Crohn's Disease treatment market is projected to attain a value of US$ 17.80 billion by 2033, driven by a CAGR of 4.3% between 2023 and 2033.

What are the Emerging Niches in the Crohn’s Disease (CD) Treatment Market?

Novel drug therapies, personalized treatment approaches, and biological interventions are emerging as notable niches in the Crohn's Disease treatment market.

What Country Rules the Crohn’s Disease (CD) Treatment Market?

The United States leads the Crohn's Disease treatment market with a strong pharmaceutical sector and established gastroenterology healthcare network.

What was the Crohn’s Disease (CD) Treatment Market's Past Record like?

With a slow-paced CAGR of 3.2%, the Crohn's Disease treatment market's revenues surpassed US$ 11.2 billion in 2022.

Table of Content

1. Executive Summary | Crohn’s Disease (CD) Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033

        5.3.1. Antibiotics

        5.3.2. Amino Salicylates

        5.3.3. Corticosteroids

        5.3.4. Immunomodulators

        5.3.5. Other

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        6.3.1. Hospital Pharmacies

        6.3.2. Retail Pharmacies

        6.3.3. Online Pharmacies

    6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. South Asia

        7.3.5. East Asia

        7.3.6. Oceania

        7.3.7. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Drug Type

        8.2.3. By Distribution Channel

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Type

        8.3.3. By Distribution Channel

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug Type

        9.2.3. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Type

        9.3.3. By Distribution Channel

    9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. United Kingdom

            10.2.1.2. Spain

            10.2.1.3. Germany

            10.2.1.4. Italy

            10.2.1.5. France

            10.2.1.6. Rest of Europe

        10.2.2. By Drug Type

        10.2.3. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Type

        10.3.3. By Distribution Channel

    10.4. Key Takeaways

11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. India

            11.2.1.2. Malaysia

            11.2.1.3. Indonesia

            11.2.1.4. Thailand

            11.2.1.5. Rest of South Asia

        11.2.2. By Drug Type

        11.2.3. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. By Distribution Channel

    11.4. Key Takeaways

12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Drug Type

        12.2.3. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Distribution Channel

    12.4. Key Takeaways

13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Australia

            13.2.1.2. New Zealand

        13.2.2. By Drug Type

        13.2.3. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Distribution Channel

    13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. South Africa

            14.2.1.2. GCC Countries

            14.2.1.3. Rest of Middle East and Africa

        14.2.2. By Drug Type

        14.2.3. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Type

        14.3.3. By Distribution Channel

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Drug Type

            15.1.2.2. By Distribution Channel

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Drug Type

            15.2.2.2. By Distribution Channel

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Drug Type

            15.3.2.2. By Distribution Channel

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Drug Type

            15.4.2.2. By Distribution Channel

    15.5. United Kingdom

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Drug Type

            15.5.2.2. By Distribution Channel

    15.6. Spain

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Drug Type

            15.6.2.2. By Distribution Channel

    15.7. Germany

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Drug Type

            15.7.2.2. By Distribution Channel

    15.8. Italy

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Drug Type

            15.8.2.2. By Distribution Channel

    15.9. France

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Drug Type

            15.9.2.2. By Distribution Channel

    15.10. India

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Drug Type

            15.10.2.2. By Distribution Channel

    15.11. Malaysia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Drug Type

            15.11.2.2. By Distribution Channel

    15.12. Indonesia

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Drug Type

            15.12.2.2. By Distribution Channel

    15.13. Thailand

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Drug Type

            15.13.2.2. By Distribution Channel

    15.14. China

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Drug Type

            15.14.2.2. By Distribution Channel

    15.15. Japan

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Drug Type

            15.15.2.2. By Distribution Channel

    15.16. South Korea

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Drug Type

            15.16.2.2. By Distribution Channel

    15.17. Australia

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Drug Type

            15.17.2.2. By Distribution Channel

    15.18. New Zealand

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Drug Type

            15.18.2.2. By Distribution Channel

    15.19. South Africa

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Drug Type

            15.19.2.2. By Distribution Channel

    15.20. GCC Countries

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Drug Type

            15.20.2.2. By Distribution Channel

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Drug Type

        16.3.3. By Distribution Channel

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Abbvie Inc.

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Celgene Corporation

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Genetech

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Johnson & Johnson

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Pfizer Inc.

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Prometheus Laboratories Inc. (Nestle)

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Salix Pharmaceuticals Inc.

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Takeda Pharmaceutical Ltd

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Janssen Pharmaceuticals

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Biogen

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

        17.1.11. AstraZeneca

            17.1.11.1. Overview

            17.1.11.2. Product Portfolio

            17.1.11.3. Profitability by Market Segments

            17.1.11.4. Sales Footprint

            17.1.11.5. Strategy Overview

                17.1.11.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: South Asia Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 15: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: East Asia Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 18: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 20: Oceania Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 21: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 22: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 23: Middle East and Africa Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 24: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 13: Global Market Attractiveness by Drug Type, 2023 to 2033

Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 28: North America Market Attractiveness by Drug Type, 2023 to 2033

Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Drug Type, 2023 to 2033

Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 58: Europe Market Attractiveness by Drug Type, 2023 to 2033

Figure 59: Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: South Asia Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 62: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: South Asia Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 68: South Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 70: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 71: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 72: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 73: South Asia Market Attractiveness by Drug Type, 2023 to 2033

Figure 74: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 76: East Asia Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 77: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: East Asia Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 83: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 85: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 86: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 88: East Asia Market Attractiveness by Drug Type, 2023 to 2033

Figure 89: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 91: Oceania Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 92: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 97: Oceania Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 98: Oceania Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 100: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 101: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 102: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 103: Oceania Market Attractiveness by Drug Type, 2023 to 2033

Figure 104: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 106: Middle East and Africa Market Value (US$ Million) by Drug Type, 2023 to 2033

Figure 107: Middle East and Africa Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 108: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033

Figure 109: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 110: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 111: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 112: Middle East and Africa Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 113: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 114: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 115: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 116: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 117: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 118: Middle East and Africa Market Attractiveness by Drug Type, 2023 to 2033

Figure 119: Middle East and Africa Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 120: Middle East and Africa Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Urine Monitoring Systems Market

Published : March 2023

Healthcare

Inflammatory Bowel Disease Treatment Market

Published : November 2022

Healthcare

Small Bowel Enteroscopes Market

Published : June 2022

Healthcare

Bowel Stimulators Market

Published : November 2021

Explore Healthcare Insights

View Reports

Crohn’s Disease (CD) Treatment Market